Edgewise Therapeutics, Inc. EWTX Business Segments — Operating Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s business segments — operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s business segments — operating income?
- Edgewise Therapeutics, Inc. (EWTX) reported business segments — operating income of -$54.12M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s business segments — operating income changed year-over-year?
- Edgewise Therapeutics, Inc.'s business segments — operating income decreased by 17.7% year-over-year, from -$45.96M to -$54.12M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — operating income?
- Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — operating income has grown at a 29.4% compound annual growth rate (CAGR), from -$114.36M to -$191.41M.
- What does business segments — operating income mean?
- Measures the profitability of the company's core business operations by subtracting operating expenses from revenues. For clinical-stage biopharmaceutical companies, this typically represents the cash burn rate associated with R&D and administrative activities. It serves as a primary indicator of the company's operational sustainability before considering financing activities.